Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20604406 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL20604354 | 1.00 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL14341707 | 0.83 | KDM4E (0.58) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL20238211 | 0.82 | ALDH1A1 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL1154655 | 0.82 | ALDH1A1 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL6099521 | 0.82 | ALDH1A1 (0.49) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL5185587 | 0.81 | ALDH1A1 (0.45) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| Trametol SCHEMBL22785888 | 0.79 | PPARG (0.47) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL11883633 | 0.79 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 | |
| SCHEMBL31065387 | 0.78 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3423433-B1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-12-17 | — | — | EP | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2019-07-16 | — | — | US | disclosed |
| EP-3423433-A1 | SULFAMATE DERIVATIVE COMPOUNDS, PROCESSES FOR PREPARING THEM AND THEIR USES | Bio-Pharm Solutions Co., Ltd. (KR) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351519-B2 | Sulfamate derivative compounds, processes for preparing them and their uses | STS, SULT2A1, SULT1A1 | SLC6A2 17/4885SLC6A4 11/4885SLC6A3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.